Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014

BMC Research Notes

Table 2 Prevalence of resistance to antiretroviral agents, Washington DC, 1999–2014

	Transmitted drug resistance (n = 1503)		Acquired drug resistance (n = 309)		Cumulative drug resistance (n = 3411)
	n	%	n	%	n	%
NRTIs^a
Abacavir	52	3.5	59	19.1	826	24.2
Didanosine	14	0.9	12	3.9	158	4.6
Emtricitabine	47	3.1	63	20.4	828	24.3
Lamivudine	47	3.1	63	20.4	828	24.3
Stavudine	88	5.9	23	7.4	582	17.1
Tenofovir	7	0.5	10	3.2	98	2.9
Zidovudine	82	5.5	17	5.5	524	15.4
NNRTIs^a
Efavirenz	151	10.0	76	24.6	929	27.2
Etravirine	19	1.3	11	3.6	212	6.2
Nevirapine	153	10.2	74	23.9	926	27.1
Rilpivirine	42	2.8	24	7.8	331	9.7
PIs^b
Atazanavir	27	1.8	10	3.2	181	5.3
Darunavir	0	0.0	0	0.0	0	0.0
Fosamprenavir	18	1.2	5	1.6	118	3.5
Indinavir	17	1.1	2	0.6	175	5.1
Lopinavir	22	1.5	4	1.3	166	4.9
Nelfinavir	29	1.9	0	0.0	247	7.2
Saquinavir	25	1.7	1	0.3	195	5.7
Tipranavir	13	0.9	3	1.0	117	3.4
EIs^a,c
Enfuvirtide	17	1.1	3	1.0	52	1.5
INSTIs^a
Dolutegravir	0	0.0	0	0.0	4	0.1
Elvitegravir	14	0.9	2	0.6	45	1.3
Raltegravir	9	0.6	5	1.6	50	1.5
Any ARV	308	20.5	125	40.5	1538	45.1
Any NRTI	118	7.9	71	23.0	1013	29.7
Any NNRTI	176	11.7	81	26.2	998	29.3
Any PI	86	5.7	19	6.1	498	14.6
Any EI	17	1.1	3	1.0	52	1.5
Any INSTI	14	0.9	6	1.9	60	1.8
Any 2 classes	67	4.5	42	13.6	582	17.1
Any 3 classes	18	1.2	5	1.6	228	6.7
Any 4 classes	0	0.0	1	0.3	15	0.4

NRTI, nucleoside/nucleotide analogue reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; EI, entry/fusion inhibitor; INSTI, integrase strand transfer inhibitor
^aInterpreted using 2014 International Antiviral Society-USA (IAS) HIV-1 drug mutations classification
^bInterpreted using 2014 IAS classification and 2014 Stanford HIVDB genotypic resistance interpretation algorithm
^cThe 2014 IAS classification did not include maraviroc

ISSN: 1756-0500